BIIB
Biogen Inc. · Healthcare · Drug Manufacturers - General
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +5.5% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 75.75K | $11.04M | n/a | −1 |
| Q2 2026 | 161 | 0 | 119.37M | $25.78B | +6 | −5 |
| Q1 2026 | 163 | -1 | 110.78M | $20.30B | +4 | −6 |
| Q4 2025 | 163 | 0 | 123.15M | $21.67B | +2 | −1 |
| Q3 2025 | 24 | +1 | 81.72M | $11.44B | +1 | −1 |
| Q2 2025 | 21 | 0 | 78.50M | $9.86B | n/a | n/a |
| Q1 2025 | 18 | +2 | 41.87M | $5.73B | +3 | −1 |
| Q4 2024 | 16 | -1 | 41.64M | $6.37B | n/a | −1 |
| Q3 2024 | 16 | +2 | 32.39M | $6.28B | +2 | n/a |
| Q2 2024 | 14 | n/a | 30.72M | $7.12B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 17.29M | n/a | $2.17B | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | PRIMECAP Management ✦ | 15.80M | -0.9% | $1.98B | 1.6% | ▼ Trim | 5 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 13.56M | n/a | $1.70B | 0.0% | n/c | 1 | SEC ↗ ×23 |
| 4 | State Street Global Advisors ✦ (passief) | 7.47M | +1.0% | $938.01M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.80M | +2.7% | $602.63M | 0.1% | ▲ Add | 5 | SEC ↗ ×5 |
| 6 | Geode Capital Management ✦ (passief) | 3.92M | +1.9% | $490.09M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 3.83M | +840.9% | $481.23M | 1.2% | ▲ Add | 2 | SEC ↗ |
| 8 | Norges Bank ✦ (passief) | 2.26M | +5.1% | $284.36M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Fidelity (FMR) ✦ | 1.67M | n/a | $210.27M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | D. E. Shaw & Co. ✦ | 1.37M | -13.8% | $171.58M | 0.2% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 1.36M | -0.3% | $171.41M | 0.1% | ▼ Trim | 5 | SEC ↗ ×7 |
| 12 | Renaissance Technologies ✦ | 1.05M | +29.9% | $131.25M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 833.93K | -27.6% | $104.73M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | Millennium Management ✦ | 675.50K | +59.3% | $84.84M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 624.37K | +190.7% | $78.41M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 608.59K | +12.3% | $76.43M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 507.54K | -42.3% | $63.74M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 289.14K | -3.3% | $36.31M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Adage Capital Partners ✦ | 247.94K | +250.4% | $31.14M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 20 | Marshall Wace ✦ | 165.96K | +2712.8% | $20.84M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 163.49K | +64.8% | $20.53M | 0.1% | ▲ Add | 5 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 995 houders, 132.27M aandelen, $23.30B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.